Company intelligence / Profile preview
Shanghai Gopherwood Biotech
Shanghai, Shanghai, Chinapmc.ncbi.nlm.nih.gov ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Shanghai Gopherwood Biotech is a clinical-stage biopharmaceutical company focused on innovative drug R&D, with several programs in Phase 1 and Phase 2 clinical trials targeting oncology indications such as peripheral T-cell lymphoma, advanced solid tumors, and BRCA-mutated breast cancer. Their pipeline includes small molecules, ISACs, and PROTACs against novel targets like PARP1/2, SHP2, EED, ATR, and TLR8[1].
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeImmune stimulating antibody conjugate (ISAC)Proteolysis-targeting chimera therapy (PROTAC)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Shanghai Gopherwood Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Gopherwood Biotech.